{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T23:06:35Z","timestamp":1792796795293,"version":"4.5.0"},"reference-count":158,"publisher":"Springer Science and Business Media LLC","license":[{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T00:00:00Z","timestamp":1778284800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Neurol Belg"],"DOI":"10.1007\/s13760-026-03064-2","type":"journal-article","created":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T03:25:03Z","timestamp":1778297103000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Lipid metabolism, neuroinflammation, and oxidative stress in Alzheimer disease: an integrated mechanistic review"],"prefix":"10.1007","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-0175-3885","authenticated-orcid":false,"given":"Lijuan","family":"Lai","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-5748-2612","authenticated-orcid":false,"given":"Yanfen","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4441-3395","authenticated-orcid":false,"given":"Guojun","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9654-7001","authenticated-orcid":false,"given":"Yongmei","family":"Long","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-3510-8496","authenticated-orcid":false,"given":"Cuiyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-1660-1648","authenticated-orcid":false,"given":"Chao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,9]]},"reference":[{"issue":"1","key":"3064_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5582\/bst.2024.01365","volume":"19","author":"YN Ma","year":"2025","unstructured":"Ma YN, Xia Y, Karako K, Song P, Tang W, Hu X (2025) Serum proteomics reveals early biomarkers of Alzheimer\u2019s disease: the dual role of APOE-\u03b54. Biosci Trends 19(1):1\u20139","journal-title":"Biosci Trends"},{"key":"3064_CR2","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.biopsych.2017.03.003","volume":"83","author":"N Zhao","year":"2018","unstructured":"Zhao N, Liu C-C, Qiao W, Bu G (2018) Apolipoprotein E, receptors, and modulation of Alzheimer\u2019s disease. Biol Psychiatry 83:347\u201357","journal-title":"Biol Psychiatry"},{"key":"3064_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.3233\/JAD-180740","volume":"68","author":"A Roda","year":"2019","unstructured":"Roda A, Montoliu-Gaya L, Villegas S (2019) The role of apolipoprotein E isoforms in Alzheimer\u2019s disease. J Alzheimers Dis 68:459\u2013471","journal-title":"J Alzheimers Dis"},{"key":"3064_CR4","doi-asserted-by":"publisher","first-page":"80","DOI":"10.4103\/1673-5374.375316","volume":"19","author":"M Lozupone","year":"2023","unstructured":"Lozupone M, Panza F (2023) Impact of apolipoprotein E isoforms on sporadic Alzheimer\u2019s disease: beyond the role of amyloid beta. Neural Regen Res 19:80\u201383","journal-title":"Neural Regen Res"},{"key":"3064_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2021.630502","author":"M Husain","year":"2021","unstructured":"Husain M, Laurent B, Plourde M (2021) APOE and Alzheimer\u2019s disease: from lipid transport to physiopathology and therapeutics. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2021.630502","journal-title":"Front Neurosci"},{"key":"3064_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212029","author":"M Men\u00e9ndez-Gonz\u00e1lez","year":"2024","unstructured":"Men\u00e9ndez-Gonz\u00e1lez M (2024) Therapeutic challenges derived from the interaction among apolipoprotein E, cholesterol, and amyloid in Alzheimer\u2019s disease. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms252212029","journal-title":"Int J Mol Sci"},{"key":"3064_CR7","doi-asserted-by":"publisher","first-page":"119876","DOI":"10.1016\/j.cca.2024.119876","volume":"562","author":"L Agnello","year":"2024","unstructured":"Agnello L, Gambino CM, Ciaccio AM, Piccoli T, Blandino V, Scazzone C et al (2024) Exploring the effect of APOE \u03b54 on biomarkers of neurodegeneration in Alzheimer\u2019s disease. Clin Chim Acta 562:119876","journal-title":"Clin Chim Acta"},{"key":"3064_CR8","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.neurobiolaging.2023.05.009","volume":"129","author":"YY Lim","year":"2023","unstructured":"Lim YY, Yassi N, Bransby L, Ayton S, Buckley RF, Eratne D et al (2023) CSF A\u03b2(42) and tau biomarkers in cognitively unimpaired A\u03b2- middle-aged and older APOE \u03b54 carriers. Neurobiol Aging 129:209\u201318","journal-title":"Neurobiol Aging"},{"key":"3064_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41582-019-0228-7","author":"Y Yamazaki","year":"2019","unstructured":"Yamazaki Y, Zhao N, Caulfield T, Liu C-C, Bu G (2019) Apolipoprotein E and Alzheimer disease: pathobiology and targeting strategies. Nat Rev Neurol. https:\/\/doi.org\/10.1038\/s41582-019-0228-7","journal-title":"Nat Rev Neurol"},{"key":"3064_CR10","doi-asserted-by":"publisher","DOI":"10.1186\/s12263-023-00722-5","author":"Z D\u2019Alonzo","year":"2023","unstructured":"D\u2019Alonzo Z, Lam V, Takechi R, Nesbit M, Vaccarezza M, Mamo J (2023) Peripheral metabolism of lipoprotein-amyloid beta as a risk factor for Alzheimer\u2019s disease: potential interactive effects of APOE genotype with dietary fats. Genes Nutr. https:\/\/doi.org\/10.1186\/s12263-023-00722-5","journal-title":"Genes Nutr"},{"issue":"5","key":"3064_CR11","doi-asserted-by":"publisher","first-page":"418","DOI":"10.2174\/1567205016666190321163438","volume":"16","author":"L Pinheiro","year":"2019","unstructured":"Pinheiro L, Faustino C (2019) Therapeutic strategies targeting amyloid-\u03b2 in Alzheimer\u2019s disease. Curr Alzheimer Res 16(5):418\u2013452","journal-title":"Curr Alzheimer Res"},{"key":"3064_CR12","doi-asserted-by":"publisher","DOI":"10.1002\/alz.065035","author":"G Sandhu","year":"2023","unstructured":"Sandhu G, Zailan F, Vipin A, Soo S, Kumar D, Ng K et al (2023) The novel visual cognitive assessment test correlates well with plasma oligomeric amyloid beta in patients with mild cognitive impairment. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.065035","journal-title":"Alzheimers Dement"},{"issue":"1","key":"3064_CR13","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s00401-024-02756-4","volume":"148","author":"A Kasri","year":"2024","unstructured":"Kasri A, Camporesi E, Gkanatsiou E, Boluda S, Brinkmalm G, Stimmer L et al (2024) Amyloid-\u03b2 peptide signature associated with cerebral amyloid angiopathy in familial Alzheimer\u2019s disease with APPdup and Down syndrome. Acta Neuropathol 148(1):8","journal-title":"Acta Neuropathol"},{"issue":"10","key":"3064_CR14","doi-asserted-by":"publisher","first-page":"3969","DOI":"10.1093\/brain\/awad159","volume":"146","author":"KP Kepp","year":"2023","unstructured":"Kepp KP, Robakis NK, H\u00f8ilund-Carlsen PF, Sensi SL, Vissel B (2023) The amyloid cascade hypothesis: an updated critical review. Brain 146(10):3969\u20133990","journal-title":"Brain"},{"key":"3064_CR15","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2022.936897","author":"DK Valappil","year":"2022","unstructured":"Valappil DK, Mini NJ, Dilna A, Nath S (2022) Membrane interaction to intercellular spread of pathology in Alzheimer\u2019s disease. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2022.936897","journal-title":"Front Neurosci"},{"key":"3064_CR16","doi-asserted-by":"publisher","first-page":"2560","DOI":"10.1007\/s11064-020-03121-z","volume":"45","author":"Y Zhang","year":"2020","unstructured":"Zhang Y, Zhao Y-Y, Zhang J, Yang G (2020) Mechanisms of NLRP3 inflammasome activation: its role in the treatment of Alzheimer\u2019s disease. Neurochem Res 45:2560\u20132572","journal-title":"Neurochem Res"},{"issue":"4","key":"3064_CR17","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1515\/revneuro-2019-0089","volume":"31","author":"A Majdi","year":"2020","unstructured":"Majdi A, Sadigh-Eteghad S, Rahigh Aghsan S, Farajdokht F, Vatandoust SM, Namvaran A et al (2020) Amyloid-\u03b2, tau, and the cholinergic system in Alzheimer\u2019s disease: seeking direction in a tangle of clues. Rev Neurosci 31(4):391\u2013413","journal-title":"Rev Neurosci"},{"key":"3064_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2024.107306","author":"D Shippy","year":"2024","unstructured":"Shippy D, Oliai S, Ulland T (2024) Zinc utilization by microglia in Alzheimer\u2019s disease. J Biol Chem. https:\/\/doi.org\/10.1016\/j.jbc.2024.107306","journal-title":"J Biol Chem"},{"key":"3064_CR19","doi-asserted-by":"publisher","first-page":"126518","DOI":"10.1016\/j.jtemb.2020.126518","volume":"61","author":"T Hamada","year":"2020","unstructured":"Hamada T, Aratake T, Higashi Y, Ueba Y, Shimizu T, Shimizu S et al (2020) Zinc-aggravated M1 microglia regulate astrocytic engulfment via P2\u00d77 receptors. J trace Elem Med biology: organ Soc Minerals Trace Elem 61:126518","journal-title":"J trace Elem Med biology: organ Soc Minerals Trace Elem"},{"key":"3064_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/alz.082041","author":"J Ferrari-Souza","year":"2023","unstructured":"Ferrari-Souza J, Bellaver B, Ferreira P, Povala G, Lussier F, Leffa D et al (2023) Association of reactive astrogliosis and microglial activation with tau pathology in Alzheimer\u2019s disease. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.082041","journal-title":"Alzheimers Dement"},{"key":"3064_CR21","doi-asserted-by":"publisher","DOI":"10.3390\/cells14020089","author":"EH Ahn","year":"2025","unstructured":"Ahn EH, Park JB (2025) Molecular mechanisms of Alzheimer\u2019s disease induced by amyloid-\u03b2 and tau phosphorylation along with RhoA activity: perspective of RhoA\/Rho-associated protein kinase inhibitors for neuronal therapy. Cells. https:\/\/doi.org\/10.3390\/cells14020089","journal-title":"Cells"},{"key":"3064_CR22","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.875138","author":"S Xiao","year":"2022","unstructured":"Xiao S, Liu Y-J, Lu W, Sha Z, Xu C, Yu Z-H et al (2022) Possible Neuropathology of Sleep Disturbance Linking to Alzheimer\u2019s Disease: Astrocytic and Microglial Roles. Front Cell Neurosci. https:\/\/doi.org\/10.3389\/fncel.2022.875138","journal-title":"Front Cell Neurosci"},{"key":"3064_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-021-00270-1","author":"M Wu","year":"2021","unstructured":"Wu M, Zhang M, Yin X, Chen K, Hu Z, Zhou Q et al (2021) The role of pathological tau in synaptic dysfunction in Alzheimer\u2019s diseases. Transl Neurodegener. https:\/\/doi.org\/10.1186\/s40035-021-00270-1","journal-title":"Transl Neurodegener"},{"key":"3064_CR24","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.mad.2019.01.007","volume":"178","author":"P Saha","year":"2019","unstructured":"Saha P, Sen N (2019) Tauopathy: a common mechanism for neurodegeneration and brain aging. Mech Ageing Dev 178:72\u20139","journal-title":"Mech Ageing Dev"},{"key":"3064_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2018.00338","author":"A Alonso","year":"2018","unstructured":"Alonso A, Cohen L, Corbo C, Morozova V, Elidrissi A, Phillips G et al (2018) Hyperphosphorylation of Tau Associates With Changes in Its Function Beyond Microtubule Stability. Front Cell Neurosci. https:\/\/doi.org\/10.3389\/fncel.2018.00338","journal-title":"Front Cell Neurosci"},{"key":"3064_CR26","doi-asserted-by":"publisher","first-page":"105714","DOI":"10.1016\/j.nbd.2022.105714","volume":"168","author":"J Strain","year":"2022","unstructured":"Strain J, Barth\u00e9lemy N, Horie K, Gordon B, Kilgore C, Aschenbrenner A et al (2022) CSF Tau phosphorylation at Thr205 is associated with loss of white matter integrity in autosomal dominant Alzheimer disease. Neurobiol Dis 168:105714","journal-title":"Neurobiol Dis"},{"key":"3064_CR27","doi-asserted-by":"publisher","first-page":"995","DOI":"10.4103\/aian.aian_858_22","volume":"25","author":"A Mukherjee","year":"2022","unstructured":"Mukherjee A, Biswas A (2022) CSF P-tau 231 as biomarker in Alzheimer\u2019s disease. Ann Indian Acad Neurol 25:995\u2013996","journal-title":"Ann Indian Acad Neurol"},{"key":"3064_CR28","doi-asserted-by":"crossref","unstructured":"DeFelipe J (2016) Phospho-Tau and Cognitive Decline in Alzheimer\u2019s Disease. Commentary: Tau in physiology and pathology. Front Neuroanat. 10","DOI":"10.3389\/fnana.2016.00044"},{"key":"3064_CR29","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.933084","author":"X Yin","year":"2021","unstructured":"Yin X, Qiu Y, Zhao C, Zhou Z, Bao J, Qian W (2021) The Role of Amyloid-Beta and Tau in the Early Pathogenesis of Alzheimer\u2019s Disease. Med Sci Monit. https:\/\/doi.org\/10.12659\/MSM.933084","journal-title":"Med Sci Monit"},{"key":"3064_CR30","doi-asserted-by":"publisher","unstructured":"Pradeepkiran JA, Reddy H (2021) Phosphorylated tau targeted small-molecule PROTACs for the treatment of Alzheimer\u2019s disease and Tauopathies. Biochimica et Biophysica Acta (BBA). https:\/\/doi.org\/10.1016\/j.bbadis.2021.166162","DOI":"10.1016\/j.bbadis.2021.166162"},{"key":"3064_CR31","doi-asserted-by":"crossref","unstructured":"Chen X, Reichert M, Gan L (2016) Molecular Pathways in Alzheimer\u2019s Disease and Cognitive Function: New Insights into Pathobiology of Tau. 135\u2013167","DOI":"10.1016\/B978-0-12-802851-3.00005-X"},{"key":"3064_CR32","doi-asserted-by":"crossref","unstructured":"Tripathi S, Sharma Y, Kumar D (2024) Unraveling APOE4\u2019s Role in Alzheimer\u2019s Disease: Pathologies and Therapeutic Strategies. Current protein & peptide science","DOI":"10.2174\/0113892037326839241014054430"},{"key":"3064_CR33","doi-asserted-by":"crossref","unstructured":"Lazar A, Hanbouch L, Boussicaut L, Fourmaux B, Daira P, Millan M et al (2022) Lipid Dys-Homeostasis Contributes to APOE4-Associated AD Pathology. Cells. 11","DOI":"10.20944\/preprints202209.0235.v1"},{"key":"3064_CR34","doi-asserted-by":"publisher","first-page":"2239","DOI":"10.1194\/jlr.R075630","volume":"58","author":"T-Y Chang","year":"2017","unstructured":"Chang T-Y, Yamauchi Y, Hasan M, Chang C (2017) Cellular cholesterol homeostasis and Alzheimer\u2019s disease. J Lipid Res 58:2239\u20132254","journal-title":"J Lipid Res"},{"key":"3064_CR35","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23169356","author":"C Borr\u00e0s","year":"2022","unstructured":"Borr\u00e0s C, Mercer A, Sirisi S, Alcolea D, Escol\u00e0-Gil J, Blanco-Vaca F et al (2022) HDL-like-mediated cell cholesterol trafficking in the central nervous system and Alzheimer\u2019s disease pathogenesis. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms23169356","journal-title":"Int J Mol Sci"},{"key":"3064_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911639","author":"Y Wang","year":"2022","unstructured":"Wang Y, Hao L, Wang T, Liu W, Wang L, Ju M et al (2022) 27-Hydroxycholesterol-induced dysregulation of cholesterol metabolism impairs learning and memory ability in ApoE \u03b54 transgenic mice. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms231911639","journal-title":"Int J Mol Sci"},{"key":"3064_CR37","doi-asserted-by":"crossref","unstructured":"Ramsden C, Cutler R, Li X, Keyes G (2025) Lipid-protecting disulfide bridges are the missing molecular link between ApoE4 and sporadic Alzheimer\u2019s disease in humans. bioRxiv","DOI":"10.1101\/2025.01.17.633633"},{"key":"3064_CR38","doi-asserted-by":"publisher","first-page":"105","DOI":"10.3233\/JAD-180815","volume":"68","author":"C Szoeke","year":"2019","unstructured":"Szoeke C, Goodwill A, Gorelik A, Dennerstein L, Caeyenberghs K, Simpson S et al (2019) Apolipoprotein E4 mediates the association between midlife dyslipidemia and cerebral amyloid in aging women. J Alzheimers Dis 68:105\u201314","journal-title":"J Alzheimers Dis"},{"key":"3064_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.pneurobio.2021.102032","volume":"202","author":"ZH Wang","year":"2021","unstructured":"Wang ZH, Xia Y, Liu P, Liu X, Edgington-Mitchell L, Lei K et al (2021) ApoE4 activates C\/EBP\u03b2\/\u03b4-secretase with 27-hydroxycholesterol, driving the pathogenesis of Alzheimer\u2019s disease. Prog Neurobiol 202:102032","journal-title":"Prog Neurobiol"},{"key":"3064_CR40","doi-asserted-by":"crossref","unstructured":"Wang X, Li H, Sheng Y, He B, Liu Z, Li W et al (2024) The function of sphingolipids in different pathogenesis of Alzheimer\u2019s disease: A comprehensive review, vol 171. Biomedicine & pharmacotherapy\u2009=\u2009Biomedecine & pharmacotherapie, p 116071","DOI":"10.1016\/j.biopha.2023.116071"},{"key":"3064_CR41","doi-asserted-by":"publisher","first-page":"1419253","DOI":"10.3389\/fnagi.2024.1419253","volume":"16","author":"J Mares","year":"2024","unstructured":"Mares J, Costa AP, Dartora WJ, Wartchow KM, Lazarian A, Bennett DA et al (2024) Brain and serum lipidomic profiles implicate Lands cycle acyl chain remodeling association with APOE\u03b54 and mild cognitive impairment. Front Aging Neurosci 16:1419253","journal-title":"Front Aging Neurosci"},{"key":"3064_CR42","doi-asserted-by":"crossref","unstructured":"Baker S, Wang N, Bu G, Liu C-C (2022) Effects of Microglia APOE Expression on Tau Pathology. FASEB J. 36","DOI":"10.1096\/fasebj.2022.36.S1.R4949"},{"key":"3064_CR43","doi-asserted-by":"publisher","DOI":"10.3390\/genes16030331","author":"C Perks","year":"2025","unstructured":"Perks C, Barker R, Alhadrami M, Alkahtani O, Gill E, Grishaw M et al (2025) Curious dichotomies of Apolipoprotein E function in Alzheimer\u2019s disease and cancer\u2014one explanatory mechanism of inverse disease associations? Genes. https:\/\/doi.org\/10.3390\/genes16030331","journal-title":"Genes"},{"key":"3064_CR44","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1016\/j.freeradbiomed.2017.08.021","volume":"112","author":"S Dixit","year":"2017","unstructured":"Dixit S, Fessel J, Harrison F (2017) Mitochondrial dysfunction in the APP\/PSEN1 mouse model of Alzheimer\u2019s disease and a novel protective role for ascorbate. Free Radic Biol Med 112:515\u2013523","journal-title":"Free Radic Biol Med"},{"key":"3064_CR45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1484373","author":"S Wang","year":"2025","unstructured":"Wang S, Liao Z, Zhang Q, Han X, Liu C, Wang J (2025) Mitochondrial dysfunction in Alzheimer\u2019s disease: a key frontier for future targeted therapies. Front Immunol. https:\/\/doi.org\/10.3389\/fimmu.2024.1484373","journal-title":"Front Immunol"},{"key":"3064_CR46","doi-asserted-by":"publisher","DOI":"10.14412\/2074-2711-2022-4-68-74","volume-title":"The role of oxidative stress in the development of Alzheimer\u2019s disease","author":"V Nikolenko","year":"2022","unstructured":"Nikolenko V, Rizaeva N, Bulygin K, Anokhina V, Bolotskaya A (2022) The role of oxidative stress in the development of Alzheimer\u2019s disease. Neurology, Neuropsychiatry, Psychosomatics"},{"key":"3064_CR47","unstructured":"Yucheng C, Zhe W (2016) Research progress of the relationship between mitochondrial dysfunction and Alzheimer\u2019s disease"},{"key":"3064_CR48","doi-asserted-by":"publisher","first-page":"3489","DOI":"10.1111\/bph.14585","volume":"176","author":"JP Ortiz","year":"2019","unstructured":"Ortiz JP, Swerdlow R (2019) Mitochondrial dysfunction in Alzheimer\u2019s disease: role in pathogenesis and novel therapeutic opportunities. Br J Pharmacol 176:3489\u20133507","journal-title":"Br J Pharmacol"},{"key":"3064_CR49","first-page":"7698560","volume":"2020","author":"Y Li","year":"2020","unstructured":"Li Y, Lu J, Cao X, Zhao H, Gao L, Xia P et al (2020) A Newly Synthesized Rhamnoside Derivative Alleviates Alzheimer\u2019s Amyloid-\u03b2-Induced Oxidative Stress, Mitochondrial Dysfunction, and Cell Senescence through Upregulating SIRT3. Oxid Med Cell Longev 2020:7698560","journal-title":"Oxid Med Cell Longev"},{"key":"3064_CR50","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2021.04.004","author":"V Sharma","year":"2021","unstructured":"Sharma V, Singh T, Mehta V (2021) Stressed mitochondria: a target to intrude alzheimer\u2019s disease. Mitochondrion. https:\/\/doi.org\/10.1016\/j.mito.2021.04.004","journal-title":"Mitochondrion"},{"key":"3064_CR51","doi-asserted-by":"publisher","DOI":"10.1016\/j.mito.2023.05.007","author":"T Alqahtani","year":"2023","unstructured":"Alqahtani T, Deore S, Kide A, Shende B, Sharma R, Chakole R et al (2023) Mitochondrial dysfunction and oxidative stress in Alzheimer\u2019s disease, and Parkinson\u2019s disease, Huntington\u2019s disease and Amyotrophic Lateral Sclerosis -an updated review. Mitochondrion. https:\/\/doi.org\/10.1016\/j.mito.2023.05.007","journal-title":"Mitochondrion"},{"key":"3064_CR52","unstructured":"Ramesh S, Govindarajulu M, Jones E, Suppiramaniam V, Moore T, Dhanasekaran M (2018) Mitochondrial dysfunction and the role of Mitophagy in Alzheimer\u2019s Disease 1 MedDocs eBooks"},{"key":"3064_CR53","doi-asserted-by":"publisher","first-page":"459","DOI":"10.14336\/AD.2023.0718","volume":"15","author":"Y Yu","year":"2023","unstructured":"Yu Y, Chen R, Mao K, Deng M, Li Z (2023) The role of glial cells in synaptic dysfunction: insights into Alzheimer\u2019s disease mechanisms. Aging Dis 15:459\u2013479","journal-title":"Aging Dis"},{"key":"3064_CR54","first-page":"79","volume":"12 3","author":"S Ramaswamy","year":"2019","unstructured":"Ramaswamy S, Bhagavan S, Kaur H, Giler G, Kempuraj D, Thangavel R et al (2019) Glia Maturation Factor in the Pathogenesis of Alzheimer\u2019s disease. Open access J Neurol Neurosurg 12 3:79\u201382","journal-title":"Open access J Neurol Neurosurg"},{"key":"3064_CR55","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2147\/JIR.S86958","volume":"9","author":"M Bronzuoli","year":"2016","unstructured":"Bronzuoli M, Iacomino A, Steardo L, Scuderi C (2016) Targeting neuroinflammation in Alzheimer\u2019s disease. J Inflamm Res 9:199\u2013208","journal-title":"J Inflamm Res"},{"key":"3064_CR56","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.molimm.2021.12.018","volume":"142","author":"JB Ruganzu","year":"2021","unstructured":"Ruganzu JB, Peng X, He Y, Wu X, Zheng Q, Ding B et al (2021) Downregulation of TREM2 expression exacerbates neuroinflammatory responses through TLR4-mediated MAPK signaling pathway in a transgenic mouse model of Alzheimer\u2019s disease. Mol Immunol 142:22\u201336","journal-title":"Mol Immunol"},{"key":"3064_CR57","doi-asserted-by":"publisher","DOI":"10.1186\/s41232-023-00277-3","author":"A Sobue","year":"2023","unstructured":"Sobue A, Komine O, Yamanaka K (2023) Neuroinflammation in Alzheimer\u2019s disease: microglial signature and their relevance to disease. Inflamm Regen. https:\/\/doi.org\/10.1186\/s41232-023-00277-3","journal-title":"Inflamm Regen"},{"key":"3064_CR58","doi-asserted-by":"publisher","first-page":"287","DOI":"10.2147\/ITT.S455881","volume":"13","author":"H Yan","year":"2024","unstructured":"Yan H, Wang W, Cui T, Shao Y, Li M, Fang L et al (2024) Advances in the Understanding of the Correlation Between Neuroinflammation and Microglia in Alzheimer\u2019s Disease. ImmunoTargets Therapy 13:287\u2013304","journal-title":"ImmunoTargets Therapy"},{"key":"3064_CR59","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252211941","author":"F Roveta","year":"2024","unstructured":"Roveta F, Bonino L, Piella E, Rainero I, Rubino E (2024) Neuroinflammatory biomarkers in Alzheimer\u2019s disease: from pathophysiology to clinical implications. Int J Mol Sci. https:\/\/doi.org\/10.3390\/ijms252211941","journal-title":"Int J Mol Sci"},{"key":"3064_CR60","doi-asserted-by":"publisher","first-page":"401","DOI":"10.14283\/jpad.2023.54","volume":"10","author":"A Bieger","year":"2023","unstructured":"Bieger A, Rocha A, Bellaver B, Machado L, Da Ros L, Borelli W et al (2023) Neuroinflammation biomarkers in the AT(N) framework across the Alzheimer\u2019s disease continuum. J Prev Alzheimers Dis 10:401\u201317","journal-title":"J Prev Alzheimers Dis"},{"key":"3064_CR61","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.1093\/brain\/awy132","volume":"141 7","author":"H Hampel","year":"2018","unstructured":"Hampel H, Mesulam M, Cuello A, Farlow M, Giacobini E, Grossberg G et al (2018) The cholinergic system in the pathophysiology and treatment of Alzheimer\u2019s disease. Brain 141 7:1917\u20131933","journal-title":"Brain"},{"key":"3064_CR62","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1097\/FBP.0000000000000300","volume":"28","author":"V Douchamps","year":"2017","unstructured":"Douchamps V, Mathis C (2017) A second wind for the cholinergic system in Alzheimer\u2019s therapy. Behav Pharmacol 28:112","journal-title":"Behav Pharmacol"},{"key":"3064_CR63","doi-asserted-by":"publisher","DOI":"10.3390\/molecules23123230","author":"D Volpato","year":"2018","unstructured":"Volpato D, Holzgrabe U (2018) Designing hybrids targeting the cholinergic system by modulating the muscarinic and nicotinic receptors: a concept to treat Alzheimer\u2019s disease. Molecules. https:\/\/doi.org\/10.3390\/molecules23123230","journal-title":"Molecules"},{"key":"3064_CR64","doi-asserted-by":"publisher","DOI":"10.1016\/j.pscychresns.2020.111099","author":"T Petrova","year":"2020","unstructured":"Petrova T, Orellana C, Jelic V, Oeksengaard A, Snaedal J, H\u00f8gh P et al (2020) Cholinergic dysfunction, neurodegeneration, and amyloid-beta pathology in neurodegenerative diseases. Psychiatry Res Neuroimaging. https:\/\/doi.org\/10.1016\/j.pscychresns.2020.111099","journal-title":"Psychiatry Res Neuroimaging"},{"key":"3064_CR65","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.neurobiolaging.2017.05.014","volume":"57","author":"P McKeever","year":"2017","unstructured":"McKeever P, Kim T, Hesketh A, MacNair L, Miletic D, Favrin G et al (2017) Cholinergic neuron gene expression differences captured by translational profiling in a mouse model of Alzheimer\u2019s disease. Neurobiol Aging 57:104\u2013119","journal-title":"Neurobiol Aging"},{"key":"3064_CR66","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.1007\/s00259-016-3349-x","volume":"43","author":"R Roy","year":"2016","unstructured":"Roy R, Niccolini F, Pagano G, Politis M (2016) Cholinergic imaging in dementia spectrum disorders. Eur J Nucl Med Mol Imaging 43:1376\u20131386","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"3064_CR67","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1111\/jnc.15243","volume":"158","author":"C Metz","year":"2020","unstructured":"Metz C, Pavlov V (2020) Treating disorders across the lifespan by modulating cholinergic signaling with galantamine. J Neurochem 158:1359\u20131380","journal-title":"J Neurochem"},{"key":"3064_CR68","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awac096","author":"E Giacobini","year":"2022","unstructured":"Giacobini E, Cuello A, Fisher A (2022) Reimagining cholinergic therapy for Alzheimer\u2019s disease. Brain. https:\/\/doi.org\/10.1093\/brain\/awac096","journal-title":"Brain"},{"key":"3064_CR69","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1080\/14737175.2024.2400683","volume":"24","author":"T Milos","year":"2024","unstructured":"Milos T, Vuic B, Balic N, Farkas V, Erjavec N, \u0160trac \u0160 et al (2024) Cerebrospinal fluid in the differential diagnosis of Alzheimer\u2019s disease: an update of the literature. Expert Rev Neurother 24:1063\u20131079","journal-title":"Expert Rev Neurother"},{"key":"3064_CR70","doi-asserted-by":"publisher","DOI":"10.1002\/alz.051799","author":"N Vilor-Tejedor","year":"2021","unstructured":"Vilor-Tejedor N, Ciampa I, Operto G, Falc\u00f3n C, Su\u00e1rez-Calvet M, Crous-Bou M et al (2021) Perivascular spaces are associated with tau pathophysiology and synaptic dysfunction in early Alzheimer\u2019s continuum. Alzheimers Res Ther. https:\/\/doi.org\/10.1002\/alz.051799","journal-title":"Alzheimers Res Ther"},{"key":"3064_CR71","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00401-018-1932-x","volume":"136","author":"J Molinuevo","year":"2018","unstructured":"Molinuevo J, Ayton S, Batrla R, Bednar M, Bittner T, Cummings J et al (2018) Current state of Alzheimer\u2019s fluid biomarkers. Acta Neuropathol 136:821\u201353","journal-title":"Acta Neuropathol"},{"issue":"4","key":"3064_CR72","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1016\/j.jalz.2017.11.015","volume":"14","author":"H Hampel","year":"2018","unstructured":"Hampel H, Toschi N, Baldacci F, Zetterberg H, Blennow K, Kilimann I et al (2018) Alzheimer\u2019s disease biomarker-guided diagnostic workflow using the added value of six combined cerebrospinal fluid candidates: A\u03b2(1\u201342), total-tau, phosphorylated-tau, NFL, neurogranin, and YKL-40. Alzheimers Dement 14(4):492\u2013501","journal-title":"Alzheimers Dement"},{"issue":"3","key":"3064_CR73","doi-asserted-by":"publisher","DOI":"10.1002\/dad2.70157","volume":"17","author":"BM Asken","year":"2025","unstructured":"Asken BM, Wang WE, Arias F, Levy SA, Barker WW, Rosselli M et al (2025) Sex and ethnicity in early-onset Alzheimer\u2019s disease biomarkers and global function. Alzheimers Dement (Amst) 17(3):e70157","journal-title":"Alzheimers Dement (Amst)"},{"key":"3064_CR74","doi-asserted-by":"publisher","DOI":"10.1002\/alz.055153","author":"C Cicognola","year":"2021","unstructured":"Cicognola C, Janelidze S, Palmqvist S, Suridjan I, Kollmorgen G, Mattsson-Carlgren N et al (2021) Effects of APOE genotype, age and sex on cerebrospinal fluid biomarkers measured with NeuroToolKit in the Longitudinal Swedish Biofinder Cohort. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.055153","journal-title":"Alzheimers Dement"},{"key":"3064_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.00149","author":"L Abdullah","year":"2020","unstructured":"Abdullah L, Crawford F, Tsolaki M, B\u00f6rjesson-Hanson A, Rikkert MO, Pasquier F et al (2020) The influence of baseline Alzheimer\u2019s disease severity on cognitive decline and CSF biomarkers in the NILVAD Trial. Front Neurol. https:\/\/doi.org\/10.3389\/fneur.2020.00149","journal-title":"Front Neurol"},{"key":"3064_CR76","doi-asserted-by":"publisher","DOI":"10.3343\/alm.2024.0498","author":"H Chae","year":"2025","unstructured":"Chae H, Kim H, Kim Y-J, Ji H, Oh E-J, Yang DW (2025) Diagnostic performance of eight blood-based biomarkers in a well-characterized Korean cohort of preclinical Alzheimer\u2019s disease. Ann Lab Med. https:\/\/doi.org\/10.3343\/alm.2024.0498","journal-title":"Ann Lab Med"},{"key":"3064_CR77","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-023-01174-0","author":"Y Guo","year":"2023","unstructured":"Guo Y, Shen XN, Wang H-F, Chen SD, Zhang Y-R, Chen S-F et al (2023) The dynamics of plasma biomarkers across the Alzheimer\u2019s continuum. Alzheimers Res Ther. https:\/\/doi.org\/10.1186\/s13195-023-01174-0","journal-title":"Alzheimers Res Ther"},{"key":"3064_CR78","doi-asserted-by":"publisher","DOI":"10.1177\/13872877251340955","author":"Q Qin","year":"2025","unstructured":"Qin Q, Xia X, Qu J, Guan Z, Yin Y, Chang J et al (2025) Blood biomarkers of amyloid and tau pathologies, brain degeneration, inflammation, and oxidative stress in early- and late-onset Alzheimer\u2019s disease. J Alzheimers Dis. https:\/\/doi.org\/10.1177\/13872877251340955","journal-title":"J Alzheimers Dis"},{"key":"3064_CR79","doi-asserted-by":"crossref","unstructured":"Simr\u00e9n J, Leuzy A, Karikari T, Hye A, Mattsson N, Hansson O et al (2020) Ultrasensitive blood biomarkers to predict cognitive decline and diagnose Alzheimer\u2019s disease in the absence of AT(N) classification as the reference standard, vol 16. Alzheimer\u2019s & Dementia","DOI":"10.1002\/alz.041808"},{"issue":"1","key":"3064_CR80","doi-asserted-by":"publisher","first-page":"355","DOI":"10.3233\/ADR-230029","volume":"7","author":"MV Pais","year":"2023","unstructured":"Pais MV, Forlenza OV, Diniz BS (2023) Plasma biomarkers of Alzheimer\u2019s disease: a review of available assays, recent developments, and implications for clinical practice. J Alzheimers Dis Rep 7(1):355\u2013380","journal-title":"J Alzheimers Dis Rep"},{"issue":"23","key":"3064_CR81","doi-asserted-by":"publisher","first-page":"2289","DOI":"10.1001\/jama.2019.7534","volume":"321","author":"D Wolk","year":"2019","unstructured":"Wolk D, Salloway S, Dickerson B (2019) Putting the new Alzheimer disease amyloid, tau, neurodegeneration (AT[N]) diagnostic system to the test. JAMA 321(23):2289\u201391","journal-title":"JAMA"},{"key":"3064_CR82","doi-asserted-by":"publisher","DOI":"10.1002\/VIW.20230025","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Zhang C, Liu J, Shao H (2023) Alzheimer\u2019s disease: potential pathogenesis and imaging findings. VIEW. https:\/\/doi.org\/10.1002\/VIW.20230025","journal-title":"VIEW"},{"key":"3064_CR83","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1007\/978-1-4939-7704-8_12","volume":"1750","author":"I Mainta","year":"2018","unstructured":"Mainta I, Vargas M, Trombella S, Frisoni G, Unschuld P, Garibotto V (2018) Hybrid PET-MRI in Alzheimer\u2019s disease research. Methods Mol Biol 1750:185\u2013200","journal-title":"Methods Mol Biol"},{"key":"3064_CR84","doi-asserted-by":"publisher","first-page":"5424","DOI":"10.1002\/hbm.24782","volume":"40","author":"A Chandra","year":"2019","unstructured":"Chandra A, Valkimadi P-E, Pagano G, Cousins O, Dervenoulas G, Politis M (2019) Applications of amyloid, tau, and neuroinflammation PET imaging to Alzheimer\u2019s disease and mild cognitive impairment. Hum Brain Mapp 40:5424\u20135442","journal-title":"Hum Brain Mapp"},{"key":"3064_CR85","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.838034","author":"C Maschio","year":"2022","unstructured":"Maschio C, Ni R (2022) Amyloid and tau positron emission tomography imaging in Alzheimer\u2019s disease and other tauopathies. Front Aging Neurosci. https:\/\/doi.org\/10.3389\/fnagi.2022.838034","journal-title":"Front Aging Neurosci"},{"key":"3064_CR86","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1148\/radiol.222441","volume":"309","author":"C Lew","year":"2023","unstructured":"Lew C, Zhou L, Mazurowski M, Doraiswamy P, Petrella J (2023) MRI-based Deep Learning Assessment of Amyloid, Tau, and Neurodegeneration Biomarker Status across the Alzheimer Disease Spectrum. Radiology 309:1","journal-title":"Radiology"},{"key":"3064_CR87","doi-asserted-by":"publisher","first-page":"973","DOI":"10.3233\/JAD-230442","volume":"100","author":"F Leng","year":"2024","unstructured":"Leng F, Hinz R, Gentleman S, Dani M, Brooks D, Edison P (2024) Combined neuroinflammation and amyloid PET markers in predicting disease progression in cognitively impaired subjects. J Alzheimers Dis 100:973\u2013986","journal-title":"J Alzheimers Dis"},{"key":"3064_CR88","doi-asserted-by":"crossref","unstructured":"Vos A, Jaaskelainen O, Demeyer L, Soininen H, Vanmechelen E, Herukka S (2018) CSF-NEUROGRANIN, BUT NOT BACE1, IS AN ALZHEIMER\u2019S DISEASE SPECIFIC BIOMARKER. Alzheimer\u2019s & Dementia. 14","DOI":"10.1016\/j.jalz.2018.06.257"},{"key":"3064_CR89","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1001\/jamaneurol.2016.0086","volume":"73 5","author":"R Tarawneh","year":"2016","unstructured":"Tarawneh R, D\u2019Angelo G, Crimmins D, Herries E, Griest T, Fagan A et al (2016) Diagnostic and Prognostic Utility of the Synaptic Marker Neurogranin in Alzheimer Disease. JAMA Neurol 73 5:561\u2013571","journal-title":"JAMA Neurol"},{"key":"3064_CR90","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/j.neurobiolaging.2021.08.002","volume":"108","author":"E Willemse","year":"2021","unstructured":"Willemse E, Sieben A, Somers C, Vermeiren Y, De Roeck N, Timmers M et al (2021) Neurogranin as biomarker in CSF is non-specific to Alzheimer\u2019s disease dementia. Neurobiol Aging 108:99\u2013109","journal-title":"Neurobiol Aging"},{"key":"3064_CR91","doi-asserted-by":"publisher","first-page":"9365","DOI":"10.18632\/aging.103211","volume":"12","author":"M Xue","year":"2020","unstructured":"Xue M, Sun F-R, Ou Yn, Shen XN, Li H-Q, Huang YY et al (2020) Association of cerebrospinal fluid neurogranin levels with cognition and neurodegeneration in Alzheimer\u2019s disease. Aging 12:9365\u20139379","journal-title":"Aging"},{"key":"3064_CR92","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-016-0053-5","author":"SS S\u00f8rensen","year":"2016","unstructured":"S\u00f8rensen SS, Nygaard A, Christensen T (2016) MiRNA expression profiles in cerebrospinal fluid and blood of patients with Alzheimer\u2019s disease and other types of dementia \u2013 an exploratory study. Transl Neurodegener. https:\/\/doi.org\/10.1186\/s40035-016-0053-5","journal-title":"Transl Neurodegener"},{"key":"3064_CR93","doi-asserted-by":"publisher","DOI":"10.2174\/0122115366243970230925061819","author":"M Jain","year":"2023","unstructured":"Jain M, Agarwal S, Rana A, Tiwari A, Patil N (2023) MiRNA as an ultimate and emerging diagnostic approach for the detection of Alzheimer\u2019s disease. MicroRNA. https:\/\/doi.org\/10.2174\/0122115366243970230925061819","journal-title":"MicroRNA"},{"key":"3064_CR94","doi-asserted-by":"crossref","unstructured":"Silvestro S, Bramanti P, Mazzon E (2019) Role of miRNAs in Alzheimer\u2019s Disease and Possible Fields of Application. Int J Mol Sci 20","DOI":"10.3390\/ijms20163979"},{"key":"3064_CR95","doi-asserted-by":"publisher","DOI":"10.1002\/alz.076538","author":"J Pereira","year":"2023","unstructured":"Pereira J, Teixeira L, Caramelli P, Veloso AA, Da Concei\u00e7\u00e3o IMCA, Luizon M et al (2023) Mirnas in cerebrospinal fluid associated with Alzheimer\u2019s disease: a systematic review and pathway analysis. Alzheimers Dement. https:\/\/doi.org\/10.1002\/alz.076538","journal-title":"Alzheimers Dement"},{"issue":"4","key":"3064_CR96","doi-asserted-by":"publisher","first-page":"1567","DOI":"10.3233\/JAD-220116","volume":"88","author":"SY Chia","year":"2022","unstructured":"Chia SY, Vipin A, Ng KP, Tu H, Bommakanti A, Wang BZ et al (2022) Upregulated Blood miR-150-5p in Alzheimer\u2019s Disease Dementia Is Associated with Cognition, Cerebrospinal Fluid Amyloid-\u03b2, and Cerebral Atrophy. J Alzheimers Dis 88(4):1567\u20131584","journal-title":"J Alzheimers Dis"},{"key":"3064_CR97","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s40266-016-0372-3","volume":"33","author":"C Wong","year":"2016","unstructured":"Wong C (2016) Pharmacotherapy for Dementia: A Practical Approach to the Use of Cholinesterase Inhibitors and Memantine. Drugs Aging 33:451\u2013460","journal-title":"Drugs Aging"},{"issue":"3","key":"3064_CR98","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1684\/pnv.2016.0621","volume":"14","author":"T Desmidt","year":"2016","unstructured":"Desmidt T, Hommet C, Camus V (2016) Pharmacological treatments of behavioral and psychological symptoms of dementia in Alzheimer\u2019s disease: role of acetylcholinesterase inhibitors and memantine. G\u00e9riatrie et Psychologie Neuropsychiatrie du Viellissement 14(3):300\u20136","journal-title":"G\u00e9riatrie et Psychologie Neuropsychiatrie du Viellissement"},{"key":"3064_CR99","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1080\/14740338.2018.1524870","volume":"17","author":"S Matsunaga","year":"2018","unstructured":"Matsunaga S, Kishi T, Nomura I, Sakuma K, Okuya M, Ikuta T et al (2018) The efficacy and safety of memantine for the treatment of Alzheimer\u2019s disease. Exp Opin Drug Saf 17:1053\u20131061","journal-title":"Exp Opin Drug Saf"},{"key":"3064_CR100","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD009081.pub2","author":"C Parsons","year":"2021","unstructured":"Parsons C, Lim WY, Loy C, McGuinness B, Passmore P, Ward S et al (2021) Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia. Cochrane Database Syst Rev. https:\/\/doi.org\/10.1002\/14651858.CD009081.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"3064_CR101","first-page":"771","volume":"95 12","author":"T Epperly","year":"2017","unstructured":"Epperly T, Dunay M, Boice J (2017) Alzheimer Disease: Pharmacologic and Nonpharmacologic Therapies for Cognitive and Functional Symptoms. Am Family Phys 95 12:771\u2013778","journal-title":"Am Family Phys"},{"issue":"1","key":"3064_CR102","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s13024-021-00424-9","volume":"16","author":"J Cummings","year":"2021","unstructured":"Cummings J (2021) New approaches to symptomatic treatments for Alzheimer\u2019s disease. Mol Neurodegener 16(1):2","journal-title":"Mol Neurodegener"},{"key":"3064_CR103","doi-asserted-by":"publisher","first-page":"105831","DOI":"10.1016\/j.neubiorev.2024.105831","volume":"165","author":"I Lanni","year":"2024","unstructured":"Lanni I, Chiacchierini G, Papagno C, Santangelo V, Campolongo P (2024) Treating Alzheimer\u2019s disease with brain stimulation: From preclinical models to non-invasive stimulation in humans. Neurosci Biobehavioral Reviews 165:105831","journal-title":"Neurosci Biobehavioral Reviews"},{"issue":"1","key":"3064_CR104","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1038\/s41392-023-01484-7","volume":"8","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Chen H, Li R, Sterling K, Song W (2023) Amyloid \u03b2-based therapy for Alzheimer\u2019s disease: challenges, successes and future. Signal Transduct Target Ther 8(1):248","journal-title":"Signal Transduct Target Ther"},{"key":"3064_CR105","doi-asserted-by":"crossref","unstructured":"Rahman A, Banu Z, Rani R, Mehdiya R (2024) Unravelling Alzheimer\u2019s disease: Insights into pathophysiology, etiology, diagnostic approaches, and the promise of aducanumab, lecanemab, and donanemab. J Phytonanotechnology Pharm Sci","DOI":"10.54085\/jpps.2024.4.3.1"},{"key":"3064_CR106","doi-asserted-by":"publisher","DOI":"10.1002\/pcn5.185","author":"H Osaka","year":"2024","unstructured":"Osaka H, Nishida K, Kanazawa T (2024) Beyond lecanemab: examining Phase III potential in Alzheimer\u2019s therapeutics. Psychiatry and Clinical Neurosciences Reports. https:\/\/doi.org\/10.1002\/pcn5.185","journal-title":"Psychiatry and Clinical Neurosciences Reports"},{"issue":"1","key":"3064_CR107","doi-asserted-by":"publisher","first-page":"873","DOI":"10.3233\/ADR-230025","volume":"7","author":"DA Loeffler","year":"2023","unstructured":"Loeffler DA (2023) Antibody-mediated clearance of brain amyloid-\u03b2: mechanisms of action, effects of natural and monoclonal anti-A\u03b2 antibodies, and downstream effects. J Alzheimers Dis Rep 7(1):873\u2013899","journal-title":"J Alzheimers Dis Rep"},{"key":"3064_CR108","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2022.106631","volume":"187","author":"BP Imbimbo","year":"2023","unstructured":"Imbimbo BP, Ippati S, Watling M, Imbimbo C (2023) Role of monomeric amyloid-\u03b2 in cognitive performance in Alzheimer\u2019s disease: insights from clinical trials with secretase inhibitors and monoclonal antibodies. Pharmacol Res 187:106631","journal-title":"Pharmacol Res"},{"key":"3064_CR109","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s41983-024-00845-5","volume":"60","author":"T Ameen","year":"2024","unstructured":"Ameen T, Kashif S, Abbas SMI, Babar K, Ali SMS, Raheem A (2024) Unraveling Alzheimer\u2019s: the promise of aducanumab, lecanemab, and donanemab. Egypt J Neurol Psychiatry Neurosurg 60:1\u201312","journal-title":"Egypt J Neurol Psychiatry Neurosurg"},{"key":"3064_CR110","doi-asserted-by":"publisher","DOI":"10.1186\/s40035-025-00465-w","author":"B-H Kim","year":"2025","unstructured":"Kim B-H, Kim S, Nam Y, Park YH, Shin SM, Moon M (2025) Second-generation anti-amyloid monoclonal antibodies for Alzheimer\u2019s disease: current landscape and future perspectives. Transl Neurodegener. https:\/\/doi.org\/10.1186\/s40035-025-00465-w","journal-title":"Transl Neurodegener"},{"key":"3064_CR111","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines12112636","author":"X Qi","year":"2024","unstructured":"Qi X, Nizamutdinov D, Yi SS, Wu E, Huang J (2024) Disease modifying monoclonal antibodies and symptomatic pharmacological treatment for Alzheimer\u2019s disease. Biomedicines. https:\/\/doi.org\/10.3390\/biomedicines12112636","journal-title":"Biomedicines"},{"key":"3064_CR112","doi-asserted-by":"publisher","first-page":"1119","DOI":"10.2217\/imt-2016-0019","volume":"8 9","author":"F Panza","year":"2016","unstructured":"Panza F, Solfrizzi V, Seripa D, Imbimbo B, Lozupone M, Santamato A et al (2016) Tau-based therapeutics for Alzheimer\u2019s disease: active and passive immunotherapy. Immunotherapy 8 9:1119\u20131134","journal-title":"Immunotherapy"},{"key":"3064_CR113","doi-asserted-by":"crossref","unstructured":"Quraishe S, Cowan C, Mudher A (2017) Tau-Centric Therapies for Treating Alzheimer\u2019s Disease. 73\u201396","DOI":"10.1016\/B978-0-12-803690-7.00005-3"},{"key":"3064_CR114","doi-asserted-by":"publisher","DOI":"10.1155\/2016\/3245935","author":"F Panza","year":"2016","unstructured":"Panza F, Solfrizzi V, Seripa D, Imbimbo B, Lozupone M, Santamato A et al (2016) Tau-centric targets and drugs in clinical development for the treatment of Alzheimer\u2019s disease. Biomed Res Int. https:\/\/doi.org\/10.1155\/2016\/3245935","journal-title":"Biomed Res Int"},{"issue":"17","key":"3064_CR115","doi-asserted-by":"publisher","first-page":"7640","DOI":"10.1021\/acs.jmedchem.8b00610","volume":"61","author":"A Gandini","year":"2018","unstructured":"Gandini A, Bartolini M, Tedesco D, Martinez-Gonzalez L, Roca C, Campillo NE et al (2018) Tau-centric multitarget approach for Alzheimer\u2019s disease: development of first-in-class dual glycogen synthase kinase 3\u03b2 and tau-aggregation inhibitors. J Med Chem 61(17):7640\u201356","journal-title":"J Med Chem"},{"key":"3064_CR116","doi-asserted-by":"publisher","first-page":"3245935","DOI":"10.1155\/2016\/3245935","volume":"2016","author":"F Panza","year":"2016","unstructured":"Panza F, Solfrizzi V, Seripa D, Imbimbo BP, Lozupone M, Santamato A et al (2016) Tau-Centric Targets and Drugs in Clinical Development for the Treatment of Alzheimer\u2019s Disease. Biomed Res Int 2016:3245935","journal-title":"Biomed Res Int"},{"key":"3064_CR117","doi-asserted-by":"crossref","unstructured":"Gopinath P, Ramesh M, Govindaraju T (2022) Chapter 17. Tau-targeting Therapeutic Strategies for Alzheimer\u2019s Disease. Alzheimer\u2019s Disease","DOI":"10.1039\/9781839162732-00487"},{"key":"3064_CR118","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.neulet.2017.03.003","volume":"646","author":"F Oliveira","year":"2017","unstructured":"Oliveira F, Chen E, Smith MC, Bertolucci P (2017) Longitudinal lipid profile variations and clinical change in Alzheimer\u2019s disease dementia. Neurosci Lett 646:36\u201342","journal-title":"Neurosci Lett"},{"key":"3064_CR119","doi-asserted-by":"publisher","DOI":"10.1186\/s13195-022-01084-7","author":"B Ebright","year":"2022","unstructured":"Ebright B, Assante I, Poblete R, Wang S, Duro M, Bennett D et al (2022) Eicosanoid lipidome activation in post-mortem brain tissues of individuals with APOE4 and Alzheimer\u2019s dementia. Alzheimers Res Ther. https:\/\/doi.org\/10.1186\/s13195-022-01084-7","journal-title":"Alzheimers Res Ther"},{"key":"3064_CR120","doi-asserted-by":"crossref","unstructured":"Patil S, Kuehn B, McCullough C, Bates D, Hazim H, Diallo M et al (2025) Discovery of Isobavachin, a Natural Flavonoid, as an Apolipoprotein E4 (ApoE4) Structure Corrector for Alzheimer\u2019s Disease. Molecules. 30","DOI":"10.1101\/2025.01.03.631209"},{"key":"3064_CR121","doi-asserted-by":"publisher","DOI":"10.3389\/fnins.2024.1430465","author":"Y Cao","year":"2024","unstructured":"Cao Y, Zhao L-W, Chen Z-X, Li S-H (2024) New insights in lipid metabolism: potential therapeutic targets for the treatment of Alzheimer\u2019s disease. Front Neurosci. https:\/\/doi.org\/10.3389\/fnins.2024.1430465","journal-title":"Front Neurosci"},{"key":"3064_CR122","doi-asserted-by":"publisher","first-page":"1120","DOI":"10.1007\/s13311-023-01375-3","volume":"20","author":"A Valencia-Olvera","year":"2023","unstructured":"Valencia-Olvera A, Balu D, Faulk N, Amiridis A, Wang Y-T, Pham C et al (2023) Inhibition of ACAT as a Therapeutic Target for Alzheimer\u2019s Disease Is Independent of ApoE4 Lipidation. Neurotherapeutics 20:1120\u20131137","journal-title":"Neurotherapeutics"},{"key":"3064_CR123","doi-asserted-by":"publisher","DOI":"10.3390\/nu15133004","author":"N Martens","year":"2023","unstructured":"Martens N, Zhan N, Voortman G, Leijten F, Van Rheenen C, Van Leerdam S et al (2023) Activation of liver X receptors and peroxisome proliferator-activated receptors by lipid extracts of brown seaweeds: a potential application in Alzheimer\u2019s disease? Nutrients. https:\/\/doi.org\/10.3390\/nu15133004","journal-title":"Nutrients"},{"issue":"6","key":"3064_CR124","doi-asserted-by":"publisher","first-page":"101089","DOI":"10.1016\/j.xcrm.2023.101089","volume":"4","author":"FM Elahi","year":"2023","unstructured":"Elahi FM, Alladi S, Black SE, Claassen J, DeCarli C, Hughes TM et al (2023) Clinical trials in vascular cognitive impairment following SPRINT-MIND: An international perspective. Cell Rep Med 4(6):101089","journal-title":"Cell Rep Med"},{"issue":"4","key":"3064_CR125","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1002\/biof.2039","volume":"50","author":"T Abdul-Rahman","year":"2024","unstructured":"Abdul-Rahman T, Awuah WA, Mikhailova T, Kalmanovich J, Mehta A, Ng JC et al (2024) Antioxidant, anti-inflammatory and epigenetic potential of curcumin in Alzheimer\u2019s disease. Biofactors 50(4):693\u2013708","journal-title":"Biofactors"},{"issue":"4","key":"3064_CR126","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1111\/bph.17373","volume":"182","author":"G Tao","year":"2025","unstructured":"Tao G, Wang X, Wang J, Ye Y, Zhang M, Lang Y et al (2025) Dihydro-resveratrol ameliorates NLRP3 inflammasome-mediated neuroinflammation via Bnip3-dependent mitophagy in Alzheimer\u2019s disease. Br J Pharmacol 182(4):1005\u20131024","journal-title":"Br J Pharmacol"},{"key":"3064_CR127","doi-asserted-by":"crossref","unstructured":"Mir R, Shah AJ, Mohi-Ud-Din R, Pottoo F, Dar M, Jachak S et al (2020) Natural Anti-inflammatory compounds as Drug candidates in Alzheimer\u2019s disease. Curr Med Chem","DOI":"10.2174\/0929867327666200730213215"},{"key":"3064_CR128","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.204.Supp.160.15","author":"A Kulkarni","year":"2020","unstructured":"Kulkarni A, Sajith A, Zhang C, Hao J, Bowen J (2020) Small molecule prevents inflammation in microglia by targeting the NLRP3 inflammasome. J Immunol. https:\/\/doi.org\/10.4049\/jimmunol.204.Supp.160.15","journal-title":"J Immunol"},{"key":"3064_CR129","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s11011-018-0332-1","volume":"34","author":"N Saini","year":"2019","unstructured":"Saini N, Singh D, Sandhir R (2019) Bacopa monnieri prevents colchicine-induced dementia by anti-inflammatory action. Metab Brain Dis 34:505\u2013518","journal-title":"Metab Brain Dis"},{"issue":"7","key":"3064_CR130","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2025.110381","volume":"301","author":"S Yang","year":"2025","unstructured":"Yang S, Huang H, Jiang K, Peng Y, Liang Z, Gong X et al (2025) Colchicine inhibits vascular calcification by suppressing inflammasome activation through the enhancement of the Sirt2-PP2Ac signaling pathway. J Biol Chem 301(7):110381","journal-title":"J Biol Chem"},{"issue":"2","key":"3064_CR131","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1177\/10738584241254118","volume":"31","author":"Q Shi","year":"2025","unstructured":"Shi Q, Gutierrez RA, Bhat MA (2025) Microglia, Trem2, and neurodegeneration. Neuroscientist 31(2):159\u201376","journal-title":"Neuroscientist"},{"key":"3064_CR132","first-page":"434","volume":"18","author":"S Wang","year":"2022","unstructured":"Wang S, Fu X-X, Duan R, Wei B, Cao H-M, Yan E et al (2022) The Alzheimer\u2019s disease-associated gene TREML2 modulates inflammation by regulating microglia polarization and NLRP3 inflammasome activation. Neural Regeneration Res 18:434\u2013438","journal-title":"Neural Regeneration Res"},{"key":"3064_CR133","doi-asserted-by":"publisher","DOI":"10.2174\/0118746098334856250106055739","author":"S Mehrabadi","year":"2025","unstructured":"Mehrabadi S (2025) Uncovering the healing power of stem cells: harnessing regenerative therapies for Alzheimer\u2019s disease. Curr Aging Sci. https:\/\/doi.org\/10.2174\/0118746098334856250106055739","journal-title":"Curr Aging Sci"},{"issue":"5","key":"3064_CR134","doi-asserted-by":"publisher","first-page":"1299","DOI":"10.1007\/s12015-025-10879-8","volume":"21","author":"M Shao","year":"2025","unstructured":"Shao M, Rahmdel M, Shayan SK, Hassannia E, khedmatgozar M, Yousefi K et al (2025) Advancements in biomaterials for stem cell differentiation. Stem Cell Rev Rep 21(5):1299\u2013310","journal-title":"Stem Cell Rev Rep"},{"key":"3064_CR135","unstructured":"Wang D, Rajappa P, Victor S, Nm S, Dp H (2019) Stieg. Stem Cells and Regenerative Therapies: Clarification of Terminology and Potential Applications in Aging and Neurodegenerative Disorders. 1\u20132"},{"key":"3064_CR136","doi-asserted-by":"crossref","unstructured":"Chen S-C (2023) An overview of stem cell-based therapy towards the treatment of Alzheimer\u2019s disease. 12611:1261136","DOI":"10.1117\/12.2669040"},{"key":"3064_CR137","doi-asserted-by":"publisher","first-page":"321","DOI":"10.3233\/JAD-180422","volume":"65","author":"S Raikwar","year":"2018","unstructured":"Raikwar S, Thangavel R, Dubova I, Ahmed M, Selvakumar PG, Kempuraj D et al (2018) Neuro-Immuno-Gene- and genome-editing-therapy for Alzheimer\u2019s disease: are we there yet? J Alzheimers Dis 65:321\u201344","journal-title":"J Alzheimers Dis"},{"key":"3064_CR138","doi-asserted-by":"publisher","first-page":"2015","DOI":"10.14336\/AD.2023.1206","volume":"15","author":"W Zhang","year":"2023","unstructured":"Zhang W, Uyemura R, Zhong K, Guo R, Zhong L (2023) Current advances and future perspectives on mesenchymal stem cell-derived extracellular vesicles in Alzheimer\u2019s disease. Aging Dis 15:2015\u20132027","journal-title":"Aging Dis"},{"issue":"4","key":"3064_CR139","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1007\/s10072-024-07871-4","volume":"46","author":"N Dong","year":"2025","unstructured":"Dong N, Ali-Khiavi P, Ghavamikia N, Pakmehr S, Sotoudegan F, Hjazi A et al (2025) Nanomedicine in the treatment of Alzheimer\u2019s disease: bypassing the blood-brain barrier with cutting-edge nanotechnology. Neurol Sci 46(4):1489\u20131507","journal-title":"Neurol Sci"},{"key":"3064_CR140","doi-asserted-by":"publisher","first-page":"357","DOI":"10.3934\/Neuroscience.2021020","volume":"8","author":"KK Siddappaji","year":"2021","unstructured":"Siddappaji KK, Gopal S (2021) Molecular mechanisms in Alzheimer\u2019s disease and the impact of physical exercise with advancements in therapeutic approaches. AIMS Neurosci 8:357\u2013389","journal-title":"AIMS Neurosci"},{"key":"3064_CR141","unstructured":"Carmona S, Kun-Rodrigues C, Bras J, Guerreiro R (2017) Revisiting the genetics of APOE"},{"key":"3064_CR142","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/S1474-4422(20)30412-9","volume":"20","author":"A Serrano-Pozo","year":"2021","unstructured":"Serrano-Pozo A, Das S, Hyman B (2021) APOE and Alzheimer\u2019s disease: advances in genetics, pathophysiology, and therapeutic approaches. Lancet Neurol 20:68\u201380","journal-title":"Lancet Neurol"},{"key":"3064_CR143","doi-asserted-by":"publisher","first-page":"2450","DOI":"10.1007\/s12035-018-1237-z","volume":"56","author":"M Uddin","year":"2018","unstructured":"Uddin M, Kabir M, Mamun AA, Abdel-Daim M, Barreto G, Ashraf G (2018) APOE and Alzheimer\u2019s disease: evidence mounts that targeting APOE4 may combat Alzheimer\u2019s pathogenesis. Mol Neurobiol 56:2450\u20132465","journal-title":"Mol Neurobiol"},{"key":"3064_CR144","doi-asserted-by":"crossref","unstructured":"Zhou M, Huang T, Collins N, Zhang J, Shen H, Dai X et al (2016) APOE4 induces tau hyperphosphorylation through calpain-CDK5 signaling pathway in EFAD-Tg mice","DOI":"10.2174\/1567205013666160415154550"},{"key":"3064_CR145","doi-asserted-by":"publisher","first-page":"1917","DOI":"10.24976\/Discov.Med.202436189.179","volume":"36 189","author":"A Reiss","year":"2024","unstructured":"Reiss A, Housny M, Gulkarov S, Hossain T, Locke B, Srivastava A et al (2024) Role of Apolipoprotein E in Alzheimer\u2019s Disease Pathogenesis, Prognosis and Treatment. Discov Med 36 189:1917\u20131932","journal-title":"Discov Med"},{"key":"3064_CR146","doi-asserted-by":"crossref","unstructured":"Steward A, Biel D, Dewenter A, Roemer S, Wagner F, Dehsarvi A et al (2023) ApoE4 and Connectivity-Mediated Spreading of Tau Pathology at Lower Amyloid Levels. JAMA Neurol","DOI":"10.1002\/alz.074017"},{"key":"3064_CR147","doi-asserted-by":"crossref","unstructured":"Serrano E, Sanz P, Barrantes F (2021) The Impact of Apolipoprotein E Allelic Variants on Alzheimer\u2019s Disease. 397\u2013418","DOI":"10.1007\/978-3-030-61721-9_29"},{"issue":"4","key":"3064_CR148","doi-asserted-by":"publisher","first-page":"470","DOI":"10.1001\/jamaneurol.2019.4421","volume":"77","author":"J Therriault","year":"2020","unstructured":"Therriault J, Benedet AL, Pascoal TA, Mathotaarachchi S, Chamoun M, Savard M et al (2020) Association of Apolipoprotein E \u03b54 With Medial Temporal Tau Independent of Amyloid-\u03b2. JAMA Neurol 77(4):470\u2013479","journal-title":"JAMA Neurol"},{"key":"3064_CR149","doi-asserted-by":"publisher","DOI":"10.1186\/s13024-022-00566-4","author":"R Fern\u00e1ndez-Calle","year":"2022","unstructured":"Fern\u00e1ndez-Calle R, Konings S, Fronti\u00f1\u00e1n-Rubio J, Garc\u00eda-Revilla J, Camprub\u00ed-Ferrer L, Svensson M et al (2022) APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer\u2019s disease pathology and brain diseases. Mol Neurodegener. https:\/\/doi.org\/10.1186\/s13024-022-00566-4","journal-title":"Mol Neurodegener"},{"issue":"10","key":"3064_CR150","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1042\/BCJ20180068","volume":"475","author":"I Dafnis","year":"2018","unstructured":"Dafnis I, Raftopoulou C, Mountaki C, Megalou E, Zannis VI, Chroni A (2018) ApoE isoforms and carboxyl-terminal-truncated apoE4 forms affect neuronal BACE1 levels and A\u03b2 production independently of their cholesterol efflux capacity. Biochem J 475(10):1839\u20131859","journal-title":"Biochem J"},{"key":"3064_CR151","doi-asserted-by":"publisher","DOI":"10.3390\/ph17040491","author":"SP Patil","year":"2024","unstructured":"Patil SP, Kuehn BR (2024) Discovery of small molecule glycolytic stimulants for enhanced ApoE lipidation in Alzheimer\u2019s disease cell model. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph17040491","journal-title":"Pharmaceuticals (Basel)"},{"issue":"7","key":"3064_CR152","doi-asserted-by":"publisher","first-page":"811","DOI":"10.1007\/s40265-024-02067-8","volume":"84","author":"JA Hey","year":"2024","unstructured":"Hey JA, Abushakra S, Blennow K, Reiman EM, Hort J, Prins ND et al (2024) Effects of oral ALZ-801\/valiltramiprosate on plasma biomarkers, brain hippocampal volume, and cognition: results of 2-year single-arm, open-label, phase 2 trial in APOE4 carriers with early Alzheimer\u2019s disease. Drugs 84(7):811\u201323","journal-title":"Drugs"},{"key":"3064_CR153","doi-asserted-by":"publisher","DOI":"10.3390\/cells14040243","author":"D Dias","year":"2025","unstructured":"Dias D, Portugal C, Relvas J, Socodato R (2025) From genetics to neuroinflammation: the impact of ApoE4 on microglial function in Alzheimer\u2019s disease. Cells. https:\/\/doi.org\/10.3390\/cells14040243","journal-title":"Cells"},{"issue":"2","key":"3064_CR154","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1002\/wps.21299","volume":"24","author":"J Torous","year":"2025","unstructured":"Torous J, Linardon J, Goldberg SB, Sun S, Bell I, Nicholas J et al (2025) The evolving field of digital mental health: current evidence and implementation issues for smartphone apps, generative artificial intelligence, and virtual reality. World Psychiatry 24(2):156\u201374","journal-title":"World Psychiatry"},{"key":"3064_CR155","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics17081041","author":"HM Yang","year":"2025","unstructured":"Yang HM (2025) Overcoming the blood-brain barrier: advanced strategies in targeted drug delivery for neurodegenerative diseases. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics17081041","journal-title":"Pharmaceutics"},{"issue":"3","key":"3064_CR156","first-page":"407","volume":"64","author":"JA Hey","year":"2025","unstructured":"Hey JA, Yu JY, Abushakra S, Schaefer JF, Power A, Kesslak P et al (2025) Clinical pharmacokinetics of oral ALZ-801\/valiltramiprosate in a 2-year phase 2 trial of APOE4 carriers with early Alzheimer\u2019s disease. Clin Pharmacokinet 64(3):407\u201324","journal-title":"Clin Pharmacokinet"},{"key":"3064_CR157","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1016\/j.jconrel.2024.01.047","volume":"367","author":"B Singh","year":"2024","unstructured":"Singh B, Day CM, Abdella S, Garg S (2024) Alzheimer\u2019s disease current therapies, novel drug delivery systems and future directions for better disease management. J Controlled Release 367:402\u2013424","journal-title":"J Controlled Release"},{"issue":"5","key":"3064_CR158","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/j.neuron.2017.11.014","volume":"96","author":"TV Huynh","year":"2017","unstructured":"Huynh TV, Liao F, Francis CM, Robinson GO, Serrano JR, Jiang H et al (2017) Age-dependent effects of apoE reduction using antisense oligonucleotides in a model of \u03b2-amyloidosis. Neuron 96(5):1013\u201323.e4","journal-title":"Neuron"}],"container-title":["Acta Neurologica Belgica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-026-03064-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13760-026-03064-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13760-026-03064-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T14:02:51Z","timestamp":1778335371000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13760-026-03064-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,9]]},"references-count":158,"alternative-id":["3064"],"URL":"https:\/\/doi.org\/10.1007\/s13760-026-03064-2","relation":{},"ISSN":["0300-9009","2240-2993"],"issn-type":[{"value":"0300-9009","type":"print"},{"value":"2240-2993","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,9]]},"assertion":[{"value":"24 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Ethical approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"<!--Emphasis Type='Bold' removed-->Consent to publish"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Clinical trial"}}]}}